Did Hedge Funds Drop The Ball On Achillion Pharmaceuticals, Inc. (ACHN) ?
Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors...
Posts Tagged ‘NASDAQ:ACHN’
Here is What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN)
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year...
Here’s What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN)
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and optimism...
Should You Buy Achillion Pharmaceuticals, Inc. (ACHN)?
Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. NASDAQ and Russell...
RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy?
The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by...
Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now
There are plenty of opportunities to invest in healthcare stocks, as there are thousands of companies, ranging from big and well-established pharmaceuticals...
Groupon Inc (GRPN), Globalstar, Inc. (GSAT) & More: Five Cheap Stocks to Buy Now
Investing in cheap stocks can be risky and inexperienced investors are usually advised to stay clear of them, even though many new investors go straight...
15 Penny Stocks Poised To Explode According To Hedge Funds
Penny stocks are usually defined as shares of small companies that trade under $1 per share, although the SEC defines a penny stock as a security that...
Wondering What’s Happening in the Financial Markets Today? Take a Look at These 34 Stories!
1. U.S. Stock Market: “Stocks rose on Wall Street on Thursday, capping a wave of declines in major world equity markets triggered by uncertainty...
This Metric Says It May Be Time to Buy Achillion Pharmaceuticals, Inc. (ACHN)
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating...
Five Cheap Healthcare Stocks Poised to Explode
The healthcare sector has witnessed a significant correction in the last 15 months, with many prominent names in the industry losing a noteworthy chunk...
Biotech Movers: Lantheus Holdings Inc (LNTH) and Achillion Pharmaceuticals, Inc. (ACHN)
As we noted last week, the close of the third quarter and the start of the final quarter of the year is when volume really starts to pick up in wider...
What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN)?
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a $1.09 billion market cap biotech company focused on solutions for infectious diseases. The company...
Five Cheap Healthcare Stocks With Hedge Fund Support
When it comes to the risk-reward ratio, there are very few sectors which can match up to healthcare. The healthcare universe boasts of several companies...
Peter Kolchinsky Is Betting Big On Achillion Pharmaceuticals, Inc. (ACHN), Wave Life Sciences (WVE) & More Heading Into 2016
Peter Kolchinsky founded RA Capital Management in 2001 and focuses mainly on healthcare stocks. One of the few hedge fund managers who actually holds...
What Do Hedge Funds Think of Achillion Pharmaceuticals, Inc. (ACHN)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data....
5 Healthcare Stocks Under $10 Ready To Pop
Investing in the healthcare sector can be tricky, especially if you’re looking for high returns and want to invest in clinical-stage companies,...
Peter Kolchinsky’s New Top Healthcare Pick And Old Favorites
Peter Kolchinsky‘s RA Capital Management recently filed its 13F with the SEC for the reporting period of June 30. Peter Kolchinsky started RA Capital...
Billionaire Steve Cohen Bullish Again (And Now More Than Ever) On Achillion Pharmaceuticals, Inc. (ACHN)
Mere months after closing its previously held stake in the company, Steve Cohen’s Point72 Asset Management appears to be more bullish than ever on Achillion...
Steadymed Ltd (STDY), Achillion Pharmaceuticals, Inc. (ACHN), & Nevro Corp (NVRO): James Flynn’s Latest Healthcare Picks
James E. Flynn of Deerfield Management, recently disclosed a stake of 1.27 million shares in Steadymed Ltd (NASDAQ:STDY). Of this stake, 737,555 shares...
CIG Wireless Corp (CIGW), Achillion Pharmaceuticals Inc (ACHN): Jeffrey Tannenbaum And Peter Kolchinsky Disclose Their Latest Moves
CIG Wireless Corp (OTCBB:CIGW), an operator of wireless and broadcast communication towers in the United States, has issued approximately 1.25 million...
Achillion Pharmaceuticals Inc (ACHN), Tenax Therapeutics Inc (TENX): Peter Kolchinsky’s Latest Equity Moves
RA Capital Management has continued the sale of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares. In a recent wave of reductions, the fund has dumped...
Achillion Pharmaceuticals, Inc. (ACHN): RA Capital Management Sells Over 2 Million Shares
RA Capital Management, managed by Peter Kolchinsky, continues to unload its stake in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). In a new filing with...
Achillion Pharmaceuticals, Inc. (ACHN): Peter Kolchinsky’s RA Capital Sells Some More Shares
Peter Kolchinsky‘s RA Capital Management, in a new filing with the Securities and Exchange Commission, has disclosed the sale of around 1.70 million...
RA Capital Management Continues To Unload Achillion Pharmaceuticals, Inc. (ACHN) Stock: Sells Further 835,293 Shares
In a new filing with the U.S. Securities and Exchange Commission, RA Capital Management, managed by Peter Kolchinsky, has disclosed holding an 18.1% passive...
Hedge Fund News: Crispin Odey, Peter Kolchinsky & T Boone Pickens
Manchester United Divides Hedge Funds’ Loyalties (WSJ) Some of Europe’s most powerful hedge fund managers are sharply divided on the outlook...
Achillion Pharmaceuticals Inc. (ACHN): RA Capital Management Cuts Stake To 19.0% From 21.1%
RA Capital Management, led by Peter Kolchinsky, disclosed in a newly amended filing with the U.S. Securities and Exchange Commission that it further reduced...
RA Capital Management Sells 800,000 Shares of Achillion Pharmaceuticals Inc. (ACHN)
RA Capital Management, managed by Peter Kolchinsky, has sold 800,000 shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) in two transactions for about...
Peter Kolchinsky, Ra Capital Management Inrease Stake in Achillion Pharmaceuticals Again
Peter Kolchinsky‘s hedge fund, Ra Capital Management disclosed upping its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) some more....
Peter Kolchinsky, Ra Capital Buy More Achillion Pharmaceuticals at $2.48/Share
Peter Kolchinsky‘s, RA Capital Management solidified its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) even more today. This time,...
Peter Kolchinsky’s RA Capital Has Been Very Active This Month
Since the beginning of November, Peter Kolchinsky‘s RA Capital Management has informed the U.S. Securities and Exchange Commission that it’...
Peter Kolchinsky’s RA Capital Boosts Stake in Achillion to 21.2%
Peter Kolchinsky and his hedge fund, RA Capital Management, boosted their position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to 21.2%, a filing...
Peter Kolchinsky, RA Capital Up Stake in Achillion Pharmaceuticals Even Higher
Peter Kolchinsky, Achillion Pharmaceuticals: This afternoon, Peter Kolchinsky and his hedge fund, RA Capital Management, strengthened their position...
Outerwall, Pandora & Achillion All Targets of Mega-Hedge Funds
Outerwall, Pandora, Achillion, hedge funds: It’s no secret that at Insider Monkey, we track hedge funds (discover why here). While a good portion...
Peter Kolchinsky’s Biotech Fund Doubles Achillion Pharmaceuticals Position
RA Capital, Achillion Pharmaceuticals: In a 13G filing with the SEC, Peter Kolchinsky‘s RA Capital disclosed that it owns nearly 15% of infectious...
Hedge Funds Are Dumping Dendreon Corporation (DNDN)
What’s a smart Dendreon Corporation (NASDAQ:DNDN) investor to do? To the average investor, there are tons of methods shareholders can use to monitor...
InterMune Inc (ITMN): Hedge Funds Aren’t Crazy About It, Insider Sentiment Unchanged
What’s a smart InterMune Inc (NASDAQ:ITMN) investor to do? To many market players, hedge funds are perceived as delayed, old financial tools of...
Is Achillion Pharmaceuticals, Inc. (ACHN) Going to Burn These Hedge Funds?
Is Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) a good investment? To the average investor, there are dozens of indicators market participants can use...
NPS Pharmaceuticals, Inc. (NPSP): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
In today’s marketplace, there are tons of gauges market participants can use to track their holdings. A duo of the most innovative are hedge fund and...
Amarin Corporation plc (ADR) (AMRN), Achillion Pharmaceuticals, Inc. (ACHN): Three Biotech Stocks That Could Double by Next Summer
Babe Ruth wasn’t afraid to swing for the fences. That’s how he became Major League Baseball’s home run king for decades. If you’...
Abbott Laboratories (ABT), AbbVie Inc (ABBV): Why Investors Should Care About Hepatitis C
Hepatitis C, caused by the hepatitis C virus (HCV), is an infectious disease affecting the liver. An estimated 130 million-200 million people worldwide...
Onyx Pharmaceuticals, Inc. (ONXX), Achillion Pharmaceuticals, Inc. (ACHN): This Week in Biotech
With the SPDR S&P Biotech Index up 20% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the...
Biotechs Lose Ground As Achillion Pharmaceuticals, Inc. (ACHN) Takes a Dive
Biotechnology’s a volatile sector that can intimidate many investors, but it’s also a landscape of stocks that can reward portfolios with...
Achillion Pharmaceuticals, Inc. (ACHN): Are Hedge Funds Right About This Stock?
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) investors should pay attention to an increase in hedge fund interest in recent months. To most stock holders...
NPS Pharmaceuticals, Inc. (NPSP): Hedge Funds and Insiders Are Bearish, What Should You Do?
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) shareholders have witnessed a decrease in hedge fund interest recently. If you’d ask most shareholders,...
Avanir Pharmaceuticals, Inc. (AVNR), Medivation Inc (MDVN) & This Week In Biotech
With the SPDR S&P Biotech Index up 31% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the...
Is Clovis Oncology Inc (CLVS) Going to Burn These Hedge Funds?
Is Clovis Oncology Inc (NASDAQ:CLVS) the right investment to pursue these days? The best stock pickers are taking a pessimistic view. The number of long...
Puma Biotechnology Inc (PBYI), Achillion Pharmaceuticals, Inc. (ACHN): Here is What Hedge Funds Think About NPS Pharmaceuticals, Inc. (NPSP)
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has seen a decrease in enthusiasm from smart money in recent months. According to most investors, hedge funds...
3 Horrendous Health-Care Stocks This Week: Rigel Pharmaceuticals, Inc. (RIGL), Achillion Pharmaceuticals, Inc. (ACHN)
The Motley Fool’s annual April Fools’ Day joke this year focused on the “hugest bubble in history” that is set to explode. For...
Galena Biopharma Inc (GALE), BIOLASE Inc (BIOL), Achillion Pharmaceuticals, Inc. (ACHN): Three Biotech Giants to Look For
In the world of biotech investing, there are many companies to choose from. When the market is on a riding stride, investment in more speculative stocks...
